Anavex Life Sciences Corp (OTCMKTS:AVXL) Updates On New Scientific Data

Anavex Life Sciences Corp (OTCMKTS:AVXL) is encouraged by the results of a new report in the latest publication of peer-reviewed journal Neuroscience Letters. The trial reflects for the first time via real-time in vivo imaging microglial inflammation, involved in destructive neurodegenerative diseases, can be cured by sigma-1 receptor activation. The role is to mitigate the negative response resulted by chronic microglia over-activation, which causes extensive cell death and numerous neurodegenerative diseases, from Alzheimer’s disease to brain injury.

The details

Anavex stated that Microglia can be defined as the immune cells of the CNS. When an individual suffers a brain injury, the immune cells move towards to clear the damaged area by taking in dying neurons. In the context of several neurological problems, chronic microglial responses are inflated and to be blamed for neurodegeneration. The trial states that the sigma-1 receptor “switches off “harmful chronic microglial actions. In addition, the response of the sigma-1 receptor was seen to be specific to harm responses as the reaction did not affect the normal microglia functions within the brain.

The expert speaks

Christopher U. Missling, PhD who is President of Anavex said that the results are very promising and seems to further validate the therapeutic potential of sigma-1 receptor agonists. It covers ANAVEX 2-73, which as of now is in a Phase 2a clinical trial in Alzheimer’s disease. Thus, it showed that when sigma-1 receptor activity is increased through agonists it could reduce the harmful impact of neuroinflammation and overstated microglial reaction in the perspective of numerous neurodegenerative diseases.

The indications

 These results point to a understandable function for the “sigma-1 receptor” in modulating microglial responses to harm. Anavex Life Sciences Corp (OTCMKTS:AVXL) is delighted to record the potential for sigma-1 agonist drug treatments to stop chronic inflammation in the case of Alzheimer’s and other CNS diseases. In last trading session, the share price of AVXL surged 1.50% to close at $0.270.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 All RIGHTS RESERVED.